Jones Peter H
Baylor College of Medicine, Houston, TX 77030, USA.
Postgrad Med. 2003 Aug;114(2 Suppl):14-21. doi: 10.3810/pgm.08.2003.suppl28.152.
Low-density lipoprotein cholesterol (LDL-C), the prime target of antilipidemic therapy, should be lowered to below 100 mg/dL for patients with coronary heart disease (CHD) and CHD risk equivalents, including diabetes, noncoronary atherosclerotic disorders, and multiple risk factors and a 10-year CHD risk greater than 20%. Five 3-hydroxy-3- methylglutaryl-CoenzymeA reductase inhibitors ("statins") are approved for use in the United States. A sixth, rosuvastatin, is awaiting approval. Of all the statins, rosuvastatin provides the greatest reductions in LDL-C along with the greatest increases in high-density lipoprotein cholesterol. The statins can be used alone, or in combination with a bile acid sequestrant, ezetimibe, or niacin in patients with mixed dyslipidemias.
低密度脂蛋白胆固醇（LDL-C）是降脂治疗的主要靶点，对于冠心病（CHD）患者以及具有CHD风险等同情况的患者，包括糖尿病、非冠状动脉粥样硬化性疾病、多种危险因素且10年CHD风险大于20%的患者，LDL-C应降至100mg/dL以下。在美国，有五种3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂（“他汀类药物”）被批准使用。第六种，瑞舒伐他汀，正在等待批准。在所有他汀类药物中，瑞舒伐他汀降低LDL-C的幅度最大，同时使高密度脂蛋白胆固醇升高的幅度也最大。他汀类药物可单独使用，或与胆汁酸螯合剂、依泽替米贝或烟酸联合用于混合性血脂异常患者。
